Drug intelligence / Profile preview

DF104B1

Development stage: Preclinical
Lead developer: Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

DF104B1 is an mRNA-based vaccine candidate developed for the prevention of COVID-19. It is designed to induce an immune response against SARS-CoV-2, the virus responsible for COVID-19. The vaccine utilizes messenger RNA technology to encode viral antigens, prompting the body’s immune system to recognize and respond to SARS-CoV-2 infection. Clinical trial registry data from China identifies it as a novel coronavirus mRNA vaccine under investigation for its safety and efficacy in preventing COVID-19[7].

Other names: 新型冠状病毒mRNA疫苗DF104B1

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on DF104B1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DF104B1.

Explore the full profile